From the publishers of JADPRO

HR+ HER2- Breast Cancer Resource Center

Advertisement

Clinicopathological and molecular features of HR + /HER2 - breast cancer patients with distinct endocrine resistance patterns

Last Updated: Monday, April 14, 2025

Researchers explored molecular features and therapeutic targets for patients with HR+ HER2- breast cancer who experienced disease recurrence. They found that patients with different relapse patterns presented with unique molecular features in their primary tumors, which can potentially guide targeted therapies.

Chinese Journal of Cancer Research
Advertisement
News & Literature Highlights
Advertisement
Advertisement